The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer

Oncogenesis

Volumn 1, Issue 6, 2012, Pages

  Richter, A M ^a   Walesch, S K ^a   Wurl P ^b   Taubert, H ^c   Dammann, R H ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b Diakoniekrankenhaus Halle ^*  (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

DNA methylation; epigenetics; gene regulation; RASSF10; tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; RASSF10 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CONTACT; COLONY FORMATION; CONTACT INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CANCER; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; SARCOMA; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84868267309     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.18     Document Type: Article

References (56)

1. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319. (Pubitemid 30437320)
2. Ponting CP, Benjamin DR. A novel family of Ras-binding domains. Trends Biochem Sci 1996; 21: 422-425. (Pubitemid 26393729)
3. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Nore1 as a potential Ras effector. J Biol Chem 1998; 273: 5439-5442. (Pubitemid 28124004)
4. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796: 114-128.
5. Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2010; 425: 303-311.
6. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011; 6: 284-292.
7. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010; 9: 264.
8. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776: 58-85. (Pubitemid 47332074)
9. Sherwood V, Manbodh R, Sheppard C, Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008; 19: 1772-1782. (Pubitemid 351805128)
10. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009; 4: 571-576.
11. Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch W, Enk A et al. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. J Invest Dermatol 2012; 132: 687-694.
12. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009 8: 42.
13. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2010; 30: 978-989.
14. Myers RM, Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC, Bernstein BE et al. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9: e1001046.
15. Chow C, Wong N, Pagano M, Lun SW, Nakayama KI, Nakayama K et al. Regulation of APC/C(Cdc20) activity by RASSF1A-APC/C(Cdc20) circuitry. Oncogene 2012; 31: 1975-1987.
16. Song MS, Song SJ, Kim SJ, Nakayama K, Nakayama KI, Lim DS. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitinmediated degradation at the G1-S transition. Oncogene 2008; 27: 3176-3185. (Pubitemid 351693166)
17. Richter AM, Schagdarsurengin U, Rastetter M, Steinmann K, Dammann RH. Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine
18. Litwiniec A, Grzanka A, Helmin-Basa A, Gackowska L, Grzanka D. Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. J Cancer Res Clin Oncol 2009; 136: 717-736.
19. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC et al. Senescenceassociated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5: 187-195.
20. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
21. Crescenzi E, Palumbo G, Brady HJ. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res 2005; 11: 8158-8171. (Pubitemid 41698760)
22. Dietrich C, Wallenfang K, Oesch F, Wieser R. Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts. Oncogene 1997; 15: 2743-2747. (Pubitemid 27507622)
23. Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K. Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 2008; 27: 4757-4767.
24. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 1994; 76: 747-760. (Pubitemid 24070658)
25. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20: 645-663. (Pubitemid 40468282)
26. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120: 3163-3172. (Pubitemid 350018407)
27. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007; 26: 7283-7301. (Pubitemid 350115980)
28. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054. (Pubitemid 37448928)
29. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 2005; 25: 3923-3933. (Pubitemid 40617644)
30. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 1998; 78: 165-174. (Pubitemid 28113455)
31. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 1981; 78: 3363-3367. (Pubitemid 11059290)
32. Hudson TH, Fain JN. Forskolin-activated adenylate cyclase. Inhibition by guanyl-5'-yl imidodiphosphate. J Biol Chem 1983; 258: 9755-9761.
33. Totsuka Y, Ferdows MS, Nielsen TB, Field JB. Effects of forskolin on adenylate cyclase, cyclic AMP, protein kinase and intermediary metabolism of the thyroid gland. Biochim Biophys Acta 1983; 756: 319-327. (Pubitemid 13095044)
34. Madelian V, La Vigne E. Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Biochem Pharmacol 1996; 51: 1739-1747. (Pubitemid 26176730)
35. Erdogan S, Houslay MD. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 1997; 321(Pt 1): 165-175.
36. Kobierski LA, Chu HM, Tan Y, Comb MJ. cAMP-dependent regulation of proenkephalin by JunD and JunB: positive and negative effects of AP-1 proteins. Proc Natl Acad Sci USA 1991; 88: 10222-10226. (Pubitemid 21915807)
37. Swanson DJ, Zellmer E, Lewis EJ. AP1 proteins mediate the cAMP response of the dopamine beta-hydroxylase gene. J Biol Chem 1998; 273: 24065-24074. (Pubitemid 28435749)
38. de Groot RP, Sassone-Corsi P. Activation of Jun/AP-1 by protein kinase A. Oncogene 1992; 7: 2281-2286.
39. Levenberg S, Yarden A, Kam Z, Geiger B. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 1999; 18: 869-876. (Pubitemid 29086263)
40. McCabe LR, Banerjee C, Kundu R, Harrison RJ, Dobner PR, Stein JL et al. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology 1996; 137: 4398-4408. (Pubitemid 26321890)
41. Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem 2005; 280: 4785-4791. (Pubitemid 40288650)
42. Akhouayri O, St-Arnaud R. Differential mechanisms of transcriptional regulation of the mouse osteocalcin gene by Jun family members. Calcif Tissue Int 2007; 80: 123-131. (Pubitemid 46294967)
43. Kameda T, Watanabe H, Iba H. C-Jun and Jun Dsuppress maturation of chondrocytes. Cell Growth Differ 1997; 8: 495-503. (Pubitemid 27273060)
44. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene 2001; 20: 2378-2389. (Pubitemid 32531296)
45. Indolfi C, Stabile E, Coppola C, Gallo A, Perrino C, Allevato G et al. Membranebound protein kinase A inhibits smooth muscle cell proliferation in vitro and in vivo by amplifying cAMP-protein kinase A signals. Circ Res 2001; 88: 319-324. (Pubitemid 32173756)
46. Abell CW, Monahan TM. The role of adenosine 3',5'-cyclic monophosphate in the regulation of mammalian cell division. J Cell Biol 1973; 59: 549-558.
47. Anderson WB, Russell TR, Carchman RA, Pastan I. Interrelationship between adenylate cyclase activity, adenosine 3':5' cyclic monophosphate phosphodiesterase activity, adenosine 3':5' cyclic monophosphate levels, and growth of cells in culture. Proc Natl Acad Sci USA 1973; 70: 3802-3805.
48. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487-496.
49. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
50. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-2534. (Pubitemid 27303718)
51. Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H et al. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 2005; 114: 442-447. (Pubitemid 40279967)
52. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46: 865-871. (Pubitemid 47549772)
53. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22: 1519-1526.
54. Steinmann K, Richter AM, Dammann RH. Epigenetic silencing of erythropoietin in human cancers. Genes Cancer 2011; 2: 65-73.
55. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-3812. (Pubitemid 36760743)
56. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005; 41: 1223-1236. (Pubitemid 40725582)